by MM360 Staff | Aug 15, 2025 | Uncategorized
Source: CureToday articles Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years. Read More
by MM360 Staff | Aug 13, 2025 | Uncategorized
Source: CureToday articles Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T cell engagers, along with potent new CELMoD drugs, all offering more targeted and effective options for patients. Read...
by MM360 Staff | Aug 12, 2025 | Uncategorized
Source: CureToday articles Ashley Dieks and Dr. Saad Z. Usmani discussed how bicycling may help patients cope with the emotional and physical challenges of their myeloma diagnosis. Read More
by MM360 Staff | Aug 1, 2025 | Uncategorized
Source: CureToday articles SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma. Read More
by MM360 Staff | Jul 30, 2025 | Uncategorized
Source: CureToday articles Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but collaborative, personalized care—including early access to cutting-edge four-drug regimens, clear communication, and...
by Victoria Langowska | Jul 23, 2025 | Uncategorized
CHICAGO — In this video, Sham Mailankody, MBBS, highlights data from a study of carfilzomib, lenalidomide and dexamethasone, with or without daratumumab, for patients with newly diagnosed multiple myeloma.“Four drugs appear to be better than three drugs, even in the...
